Skip to main content

Advertisement

Figure 3 | Orphanet Journal of Rare Diseases

Figure 3

From: Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries

Figure 3

Number of MEAs set up by AIFA, described by MEA design (according to AIFA’s terminology). Note: A single medicine may be subject to several of these mechanisms at the same time. This graph does not show details for price-volume agreements and restricting notes as these arrangements are not applicable to orphan medicinal products. Source: AIFA, 2013.

Back to article page